Colvin Greenberg, BS
University of Washington
Disclosure(s): No financial relationships to disclose
Frederic Bertino, MD
Clinical Assistant Professor; Director of Pediatric Interventional Radiology
Department of Radiology at NYU Grossman School of Medicine
Mina S. Makary, MD (he/him/his)
The Ohio State University Wexner Medical Center
Seventy-five stents were deployed during 52 procedures. Venous stents used included 43 Abre, 21 Venovo, seven Vici, and four Zilver Vena. Reconstructed veins included: superior vena cava (SVC)-to-bilateral brachiocephalic veins (BCVs) (n=12), unilateral BCV (n=12), SVC-to-unilateral BCV (n=9), SVC only (n=8), SVC-to-unilateral subclavian vein (SCV) (n=6), and unilateral BCV-to-SCV (n=5). Overall mean stent diameter was 13.7 ± 2.0-mm. Mean stent diameters of Abre, Venovo, Vici, and Zilver Vena were 13.2 ± 1.8-mm, 15.2 ± 1.8-mm, 12.3 ± 0.8-mm, and 14 ± 0-mm, respectively. Technical success was achieved in all procedures. One Venovo stent malexpansion occurred which responded to angioplasty. One patient experienced an access site hematoma at the left brachial vein which resolved without intervention. Clinical success was achieved in all patients. No stent fractures or migrations occurred. Six patients required stent revisions at mean of 124.3 ± 82.1 days after the initial procedures.
Conclusion: The use of dedicated venous stents in the upper extremity and thoracic central veins yielded excellent technical and clinical success rates without immediate adverse events.